The effect of synbiotic supplement on improvement of diabetics overweight status.

The effect of supplementation synbiotic (probiotic bacteria Lactobacillus plantarum with chicory root extract) on antioxidant and inflammatory markers in overweight diabetics

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016062628386N2

Enrollment

100

Registered

2016-08-02

Start date

2016-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention Group 1: Chicorium intybus. L powder 600 mg with probiotic bacteria L.plantarum 108 cfu/ml in capsule daily for 3 months. Intervention 2: Intervention Group 2: Probiotic

Treatment - Drugs

Placebo

Intervention Group 1: Chicorium intybus. L powder 600 mg with probiotic bacteria L.plantarum 108 cfu/ml in capsule daily for 3 months

Intervention Group 2: Probiotic bacteria L.plantarum 108 cfu/ml in capsule daily for 3 months

Intervention Group 3: Chicorium intybus. L powder 600 mg in capsule daily for 3 months

Control Group: Two grams of rice flour in capsule daily for 3 months

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: High blood glucose over 100 mg per deciliter, 20 to 75 years of age, voluntary consent for participation in the study Exclusion criteria: A special diet (such as weight loss diet) in the previous three months of the study and during the study,patients with cancer, uncontrolled diabetes, acute infectious diseases, mental illness or any other illness that can potentially rapid decline weight, person with chronic gastrointestinal disease, using systemic antibiotic 6 weeks before entering the study, using probiotics and omega-3 supplements in the previous three months of the study, identified immunodeficiency, pregnancy or breastfeeding, Participation in other clinical trials in the last 6 months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Antioxidant biomarkers. Timepoint: 3 months after intervention. Method of measurement: MDA concentration and PON activity in serum.;Inflammatory markers. Timepoint: 3 months after intervention. Method of measurement: WBC counts, Leptin and Adiponectin concentration in serum and blood.;Fasting blood Glucose. Timepoint: At starting of the study and 3 months after intervention. Method of measurement: autoanalyzer.;Lipid profile. Timepoint: 3 months after intervention. Method of measurement: autoanalyzer.	—

Measure

Time frame

Antioxidant biomarkers. Timepoint: 3 months after intervention. Method of measurement: MDA concentration and PON activity in serum.;Inflammatory markers. Timepoint: 3 months after intervention. Method of measurement: WBC counts, Leptin and Adiponectin concentration in serum and blood.;Fasting blood Glucose. Timepoint: At starting of the study and 3 months after intervention. Method of measurement: autoanalyzer.;Lipid profile. Timepoint: 3 months after intervention. Method of measurement: autoanalyzer.

—

Secondary

Measure	Time frame
Weight. Timepoint: At starting of the study and after 3 months. Method of measurement: Scale.;Body mass index. Timepoint: At starting of the study and after 3 months. Method of measurement: Weight(Kg)/height(m2).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahboobeh Mehrabani Natanzi

Alborz University of Medical Sciences

mahboobehmehrabani@yahoo.com+98 26 3458 4919

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026